Literature DB >> 4176

The pH dependence of quantitative ristocetin-induced platelet aggregation: theoretical and practical implications-a new device for maintenance of platelet-rich plasma pH.

B S Coller, B R Franza, H R Gralnick.   

Abstract

Quantitative ristocetin-induced platelet aggregation of normal platelet-rich plasma (PRP) decreased with time after PRP preparation. An increase in p H of the PRP with time proved to be responsible for this finding. Diffusion of CO2from the plasma is the prime determinant of the change in pH. Since a complex combination of factors influences CO2 diffusion (surface area-to-volume relationship, capping, mixing, etc.) The change in pH is variable with time. Thus, quantitative ristocetin aggregation should be pH controlled. A simple device for maintaining PRP pH constant by control of the ambient pCO2 was designed and found effective in keeping both pH and quantitative ristocetin aggregation constant over a prolonged period of time. It can be adapted for use in platelet aggregation studies employing other reagents. The pH dependence of ristocetin-induced platelet aggregation is consistent with other data supporting an elctrostatic interaction between the platelet, von Willebrand factor, and ristocetin. We favor a model wherein ristocetin neutralizes some of the platelet's negative change and permits the von Willebrand factor to bridge sites on separate platelets to induce agglutination.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 4176

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets.

Authors:  K J Kao; S V Pizzo; P A McKee
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

2.  Destruction of the platelet aggregating activity of ristocetin A.

Authors:  S Kuwahara; W T Chambers
Journal:  Experientia       Date:  1978-04-15

3.  Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity.

Authors:  H R Gralnick
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

4.  The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility.

Authors:  B S Coller
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

5.  A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.

Authors:  B S Coller; E I Peerschke; L E Scudder; C A Sullivan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

Review 6.  Effect of heparin and heparin fractions on platelet aggregation.

Authors:  E W Salzman; R D Rosenberg; M H Smith; J N Lindon; L Favreau
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

7.  Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin.

Authors:  B S Coller; H R Gralnick
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

8.  The platelet: life on the razor's edge between hemorrhage and thrombosis.

Authors:  Barry S Coller
Journal:  Transfusion       Date:  2014-08-05       Impact factor: 3.157

9.  The role of platelet aggregation and release in fragment D-induced pulmonary dysfunction.

Authors:  D Manwaring; P W Curreri
Journal:  Ann Surg       Date:  1980-07       Impact factor: 12.969

10.  A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.

Authors:  B S Coller
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.